The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus
Angiotensin receptor blockers (ARBs) are with increasing frequency used in arterial hypertension treatment, this class of medications is especially important in treatment of patients with obesity, metabolic syndrome and diabetes mellitus. Although not all the ARBs are the therapy of first choice in...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2019-09-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | https://syst-hypertension.ru/2075-082X/article/viewFile/33549/pdf |
| _version_ | 1818326596113661952 |
|---|---|
| author | Juliya V Zhernakova Irina E Chazova Nataliia V Blinova |
| author_facet | Juliya V Zhernakova Irina E Chazova Nataliia V Blinova |
| author_sort | Juliya V Zhernakova |
| collection | DOAJ |
| description | Angiotensin receptor blockers (ARBs) are with increasing frequency used in arterial hypertension treatment, this class of medications is especially important in treatment of patients with obesity, metabolic syndrome and diabetes mellitus. Although not all the ARBs are the therapy of first choice in these patients. The special requirements are imposed upon antihypertensive mediations for patients with arterial hypertension and metabolic disorders such as high antihypertensive activity, maximum duration of action, possibility of increase of peripheral tissues sensitivity to insulin and, subsequently, metabolic profile. Besides, these patients require the use of combined therapy already at the treatment start. There are very few ARBs combinations with thiazide diuretics that exhibit these properties. The present review discusses possibilities of new ARB azilsartan medoxomil (Edarbi®) and its combination with chlortalidone (Edarbi® Clo) in decrease of cardiovascular risk in patients with obesity, metabolic syndrome and diabetes mellitus. |
| first_indexed | 2024-12-13T12:02:53Z |
| format | Article |
| id | doaj.art-f44be6677b5748779f8583bb1c5936be |
| institution | Directory Open Access Journal |
| issn | 2075-082X 2542-2189 |
| language | Russian |
| last_indexed | 2024-12-13T12:02:53Z |
| publishDate | 2019-09-01 |
| publisher | IP Morozov P.V. |
| record_format | Article |
| series | Системные гипертензии |
| spelling | doaj.art-f44be6677b5748779f8583bb1c5936be2022-12-21T23:47:03ZrusIP Morozov P.V.Системные гипертензии2075-082X2542-21892019-09-01163364210.26442/2075082X.2019.3.19046730279The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitusJuliya V Zhernakova0Irina E Chazova1Nataliia V Blinova2National Medical Research Center for CardiologyNational Medical Research Center for CardiologyNational Medical Research Center for CardiologyAngiotensin receptor blockers (ARBs) are with increasing frequency used in arterial hypertension treatment, this class of medications is especially important in treatment of patients with obesity, metabolic syndrome and diabetes mellitus. Although not all the ARBs are the therapy of first choice in these patients. The special requirements are imposed upon antihypertensive mediations for patients with arterial hypertension and metabolic disorders such as high antihypertensive activity, maximum duration of action, possibility of increase of peripheral tissues sensitivity to insulin and, subsequently, metabolic profile. Besides, these patients require the use of combined therapy already at the treatment start. There are very few ARBs combinations with thiazide diuretics that exhibit these properties. The present review discusses possibilities of new ARB azilsartan medoxomil (Edarbi®) and its combination with chlortalidone (Edarbi® Clo) in decrease of cardiovascular risk in patients with obesity, metabolic syndrome and diabetes mellitus.https://syst-hypertension.ru/2075-082X/article/viewFile/33549/pdfarterial hypertensionobesitymetabolic syndromediabetes mellitusangiotensin receptor blockerschlortalidoneantihypertensive treatmentcombined therapycardiovascular risk |
| spellingShingle | Juliya V Zhernakova Irina E Chazova Nataliia V Blinova The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus Системные гипертензии arterial hypertension obesity metabolic syndrome diabetes mellitus angiotensin receptor blockers chlortalidone antihypertensive treatment combined therapy cardiovascular risk |
| title | The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus |
| title_full | The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus |
| title_fullStr | The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus |
| title_full_unstemmed | The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus |
| title_short | The possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity, metabolic syndrome and diabetes mellitus |
| title_sort | possibilities of angiotensin receptor blocker azilsartan medoxomil and its combination with chlortalidone in cardiovascular risk decrease in patients with obesity metabolic syndrome and diabetes mellitus |
| topic | arterial hypertension obesity metabolic syndrome diabetes mellitus angiotensin receptor blockers chlortalidone antihypertensive treatment combined therapy cardiovascular risk |
| url | https://syst-hypertension.ru/2075-082X/article/viewFile/33549/pdf |
| work_keys_str_mv | AT juliyavzhernakova thepossibilitiesofangiotensinreceptorblockerazilsartanmedoxomilanditscombinationwithchlortalidoneincardiovascularriskdecreaseinpatientswithobesitymetabolicsyndromeanddiabetesmellitus AT irinaechazova thepossibilitiesofangiotensinreceptorblockerazilsartanmedoxomilanditscombinationwithchlortalidoneincardiovascularriskdecreaseinpatientswithobesitymetabolicsyndromeanddiabetesmellitus AT nataliiavblinova thepossibilitiesofangiotensinreceptorblockerazilsartanmedoxomilanditscombinationwithchlortalidoneincardiovascularriskdecreaseinpatientswithobesitymetabolicsyndromeanddiabetesmellitus AT juliyavzhernakova possibilitiesofangiotensinreceptorblockerazilsartanmedoxomilanditscombinationwithchlortalidoneincardiovascularriskdecreaseinpatientswithobesitymetabolicsyndromeanddiabetesmellitus AT irinaechazova possibilitiesofangiotensinreceptorblockerazilsartanmedoxomilanditscombinationwithchlortalidoneincardiovascularriskdecreaseinpatientswithobesitymetabolicsyndromeanddiabetesmellitus AT nataliiavblinova possibilitiesofangiotensinreceptorblockerazilsartanmedoxomilanditscombinationwithchlortalidoneincardiovascularriskdecreaseinpatientswithobesitymetabolicsyndromeanddiabetesmellitus |